Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer's disease.

Jagan A PillaiJames BenaLynn BekrisNandan KodurTakhar KasumovJames B LeverenzSangeeta R Kashyapnull null

Published in: Alzheimer's research & therapy (2023)

Biomarkers of metabolic syndrome relate to rate of cognitive decline among MCI and dementia individuals. Elevated plasma TG/HDL-C ratio and plasma ApoA1 are associated with worse cognitive outcomes in MCI and dementia participants. CSF ApoA1 and plasma ApoA1 likely have different roles in AD progression in MCI stage.

Keyphrases

mild cognitive impairment
cognitive decline
metabolic syndrome
insulin resistance
uric acid
cardiovascular risk factors
type diabetes